These guidelines, produced by the National Institute for Health and Care Excellence (NICE), set out new recommendations for the diagnosis, treatment and care of myeloma patients with the aim of providing consistently excellent patient-focused care within the NHS in England. Update information October 2018: Recommendations 1.8.13 to 1.8.17 were replaced by NICE’s guideline on venous thromboembolism in…Download
Following consultation on the scope of the guideline we have decided to retain Improving supportive and palliative care for adults with cancer. The title of the new guideline will be changed to End of life care for adults in the last year of life: service delivery. Where there is overlap between the two guidelines we…Download
Thalidomide with an alkylating agent and a corticosteroid is recommended as an option for the first-line treatment of non-transplant eligible myeloma patients in England. In addition, bortezomib with an alkylating agent and a corticosteroid is recommended as an option for first-line treatment of non-transplant eligible patients who are intolerant to or contraindicated to thalidomide.